Point in time view as at 06/11/2023.
The Medicines for Human Use (Clinical Trials) Regulations 2004, Paragraph 2 is up to date with all changes known to be in force on or before 04 March 2025. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.
2. In the Medicines (Surgical Materials) Order 1971 F1, in article 3, for the words from “, the provisions contained in Parts I and II of the Act” to the end substitute—U.K.
“(a)the provisions contained in Parts I and II of the Act, sections 62, 64, 65 and 67 of Part III of the Act, and the provisions contained in Parts V, VI and VIII of the Act shall have effect in relation to the said articles or substances described in the Schedule to this Order, as those provisions have effect in relation to medicinal products; and
(b)the provisions of the Clinical Trials Regulations shall have effect in relation to the said articles or substances.”.
Textual Amendments
F1S.I. 1971/1267, as amended by S.I. 1994/3119.
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.
